Cargando…

Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia

INTRODUCTION: Flumatinib is a novel, oral breakpoint cluster region-abelson (BCR-ABL) tyrosine kinase inhibitor that has demonstrated manageable safety and promising efficacy in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML). METHODS: This study evaluated the pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Bo, Qi, Junyuan, Sun, Mingyuan, Zheng, Weiwei, Wei, Yongyue, Wang, Jianxiang, Zhang, Fengkui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939828/ https://www.ncbi.nlm.nih.gov/pubmed/36814813 http://dx.doi.org/10.3389/fonc.2023.1101738

Ejemplares similares

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
por: Castagnetti, Fausto, et al.
Publicado: (2021)

Management of Chronic Myeloid Leukemia in Advanced Phase
por: Bonifacio, Massimiliano, et al.
Publicado: (2019)

Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects
por: Kuang, Yun, et al.
Publicado: (2020)

Atypical presentation of patients with chronic myeloid leukemia in chronic phase—Case report
por: Ramdohr, Florian, et al.
Publicado: (2022)

Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome‐positive acute myeloid leukemia: A case report
por: Huang, Si‐Man, et al.
Publicado: (2023)

Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
por: Giallongo, Cesarina, et al.
Publicado: (2015)

Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase
por: Yılmaz, Umut, et al.
Publicado: (2022)

Debating Frontline Therapy in Chronic Myeloid Leukemia
por: Bi, Xia, et al.
Publicado: (2021)

Editorial: Advances in the treatment of chronic myeloid leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2023)

New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
por: Westerweel, Peter E., et al.
Publicado: (2019)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias
por: Bhingarkar, Aboli, et al.
Publicado: (2021)

Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience
por: Chitanava, Tamara, et al.
Publicado: (2023)

Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo
por: Liu, Ya-nan, et al.
Publicado: (2023)

A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib
por: Chen, Lili, et al.
Publicado: (2022)

Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective
por: Atallah, Ehab L., et al.
Publicado: (2022)

Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase
por: Oyogoa, Emmanuella, et al.
Publicado: (2023)

Priapism – A Rare Presentation in Chronic Myeloid Leukemia: Case Report
por: Nerli, Rajendra B., et al.
Publicado: (2015)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy
por: Andretta, Emanuela, et al.
Publicado: (2021)

The Molecular Role of HIF1α Is Elucidated in Chronic Myeloid Leukemia
por: Singh, Vivek, et al.
Publicado: (2022)

Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells
por: Chen, Yilin, et al.
Publicado: (2021)

Chronic phase of chronic myeloid leukemia presenting with myeloid sarcoma in an adolescent
por: Lee, Hee Jin, et al.
Publicado: (2020)

Unusual Presentation of Chronic Myeloid Leukemia in Chronic Phase as Multiple Soft Tissue Chloromas
por: Misra, Sunayana, et al.
Publicado: (2020)

Basic and clinical study of efficacy and adverse effects of flumatinib in Ph(+) ALL
por: Wang, Jun, et al.
Publicado: (2023)

Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report
por: Capodanno, Isabella, et al.
Publicado: (2021)

Management of Chronic Myeloid Leukemia and Pregnancy: A Bibliometric Analysis (2000-2020)
por: Wang, Yue, et al.
Publicado: (2022)

Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?
por: Elsayed, Marwa, et al.
Publicado: (2022)

Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China
por: Cheng, Fang, et al.
Publicado: (2023)

Chronic Myeloid Leukemia and Hepatoblastoma: Two Cancer Models to Link Metabolism to Stem Cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2016)

Chronic Myeloid Leukemia: A Case of Extreme Thrombocytosis Causing Syncope and Myocardial Infarction
por: Ebrahem, Rawaa, et al.
Publicado: (2016)

The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia
por: Grassi, Susanna, et al.
Publicado: (2019)

Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches
por: Izzo, Barbara, et al.
Publicado: (2019)

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
por: Kong, Jee Hyun, et al.
Publicado: (2020)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
por: Cheng, Fang, et al.
Publicado: (2023)

PB1749: APOPTOTIC EFFECT OF FLUMATINIB COMBINED WITH BCL2 INHIBITOR ON PH+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Gu, Y., et al.
Publicado: (2022)

Chronic Myeloid Leukemia: Chronic Phase Presenting as Extramedullary Presentation
por: Nanote, Vedant A, et al.
Publicado: (2022)

Phase distribution of chronic myeloid leukemia in Bangladesh
por: Mottalib, Md Abdul, et al.
Publicado: (2014)

Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase
por: Yohanan, Binoy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_62tfvp5lqdca0ldnhmj12o4612